Access and SpePharm Announce Licensing of MuGard for Europe
SpePharm Will Market MuGard in Europe for the Treatment of Oral Mucositis
Access Pharmaceuticals, Inc. and SpePharm Holding, B.V. announced the signing of a definitive licensing agreement under which SpePharm will market Access's product MuGard in Europe.
MuGard is Access' proprietary product for the management of oral mucositis, a debilitating side effect of many anticancer treatments. MuGard has received marketing allowance in the United States from the Food and Drug Administration under a 510(k) procedure. SpePharm will be responsible for marketing MuGard throughout the European Union plus Switzerland, Norway and Iceland, as well as for manufacturing and for obtaining the necessary regulatory approvals for the product in the territory.
In connection with the exclusive Licensing Agreement, SpePharm will pay Access an upfront fee and substantial royalties on net sales.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.